The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial showed that the direct thrombin inhibitor bivalirudin, with provisional glycoprotein (Gp) IIb/IIIa ...

GP IIb/IIIa antagonists are potent inhibitors of platelet aggregation. A clear understanding of the bleeding risks associated with their use is of particular importance in the cardiac ...

Cite this: Bleeding Due to Glycoprotein IIb/IIIa Receptor Inhibition During Percutaneous Coronary Intervention: Risk Factors and Management - Medscape - Nov 01, 2004.